Drug intelligence / Profile preview

AVE2635A

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Inhalation (by Dry Powder Inhaler)

Overview

AVE2635A is a small molecule drug developed by Sanofi, primarily investigated for the treatment of immune system diseases and respiratory diseases, with a particular focus on asthma. It has reached Phase 2 clinical trials as an inhaled therapy for persistent asthma. The mechanism of action and specific molecular target have not been publicly disclosed in available sources. Some references suggest it may be related to angiogenesis inhibition or glucocorticosteroid activity, but these are not confirmed in primary trial records[1][2][3]. Its development status is currently pending.

Beyond the preview

Go deeper on AVE2635A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVE2635A.

Explore the full profile